Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma

Radiotherapy and Oncology

Volumn 40, Issue 3, 1996, Pages 245-247

  Pickles, Tom ^c   Graham, Peter ^a,c   Syndikus, Isabel ^b,c   Rheaume, Dorianne E ^c   Duncan, Graeme G ^c   Green, Alex ^c   Marlow, Carol ^c  

^a ST GEORGE HOSPITAL   (Australia)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Carbogen; Glioblastoma; Nicotinamide; Radiation therapy

Indexed keywords

CARBOGEN; NICOTINAMIDE; PHENYTOIN;

ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LIVER TOXICITY; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; SEIZURE; VOMITING;

EID: 17444447006     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-8140(96)01792-6     Document Type: Article

References (15)

1. [1] Bourgeois, B.F., Dodson, W.E. and Ferrendelli, J.A. Interactions between primidone, carbamazepine, and nicotinamide. Neurology 32: 1122-1126, 1982.
2. [2] Haustermans, K., van der Kogel, A.J., Vanakcker, B. and van der Schueren, E. Influence of combined use of nicotinamide and carbogen on rat spinal cord tolerance. Radiother. Oncol. 31: 123-128, 1994.
3. [3] Hoter, A. Safety, side effects and relative lack of toxicity of nicotinic acid and nicotinamide. Schizophrenia 1: 78-87, 1969.
4. [4] Horsman, M.R., Chaplin, D.J. and Brown, J.M. Radiosensitization by nicotinamide in vivo: a greater enhancement of tumour damage compared to that of normal tissues. Radiat. Res. 109: 479-489, 1987.
5. [5] Horsman, M.R., Hansen, P.V. and Overgaard, J. Radiosensitization by nicotinamide in tumours and normal tissues: the importance of tissue oxygenation status. Int. J. Radiat. Oncol. Biol. Phys. 16: 1273-1276, 1989.
6. [6] Horsman, M.R., Hoyer, M., Honess, D., Dennis, I. and Overgaard, J. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother. Oncol. 27: 131-139, 1993.
7. [7] Kjellen, E., Joiner, M.C., Collier, J.M., Johns, H. and Rojas, A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother. Oncol. 22: 81-91, 1991.
8. 2 distribution and bioreductive enzymes in human malignant brain tumours. Int. J. Radiat. Oncol. Biol. Phys. 29: 427-431, 1994.
9. [9] Rubin, P., Hanley, J., Keys, H.M., Marcial, V. and Brady, L. Carbogen breathing during radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 5: 1963-1970, 1979.
10. 2) on the in vivo radiation response of a murine sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 2: 903-911, 1977.
11. [11] Smythe, M.A. and Umstead, G. Phenytoin hepatotoxicity: a review of the literature. DICP Ann. Pharmacol. 23: 13-18, 1989.
12. [12] Stratford, M.R.L., Rojas, A., Hall, D.W., Dennis, M.F., Dische, S., Joiner, M.C. and Hodgkiss, R.J. Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother. Oncol. 25: 37-42, 1992.
13. [13] Suit, H.D., Marshall, N. and Woerner, D. Oxygen, oxygen plus carbon dioxide, and radiation therapy of a mouse mammary carcinoma. Cancer 30: 1154-1158, 1972.
14. [14] van der Maazen, R.W.M., Thijssen, H.O.M., Kaanders, J.H.A.M., de Koster, A., Keyser, A., Prick, M.J.J., Grotenhuis, J.A., Wesseling, P. and van der Kogel, A.J. Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. Radiother. Oncol. 35: 118-122, 1995.
15. [15] Zackrisson, B., Franken, L., Henriksson, R., Littbrand, B., Stratford, M., Dennis, M., Rojas, A.M. and Denekamp, J. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). Acta Oncol. 33: 377-381, 1994.